Showing results (121-130 of 325) with videos related to
Sort By:
Pageof 33
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndromeB E Lewis, J M Walenga, D E WallisDrugs of Today (Barcelona, Spain : 1998)|July 9, 2003
Bleeding complications with glycoprotein IIb/IIIa inhibitorsO Iqbal, J M Walenga, B E Lewis, et al.Perfusion|May 4, 2001
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management testM Wallock, W P Jeske, M Bakhos, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agentsW P Jeske, A M Jay, S Haas, et al.The Journal of Burn Care & Rehabilitation|February 7, 2001
Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuriesA Kowal-Vern, V McGill, J M Walenga, et al.Thrombosis Research|July 15, 1992
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamineA Racanelli, J FareedThrombosis Research|November 1, 1992
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfateA Racanelli, J FareedThrombosis and Haemostasis|October 1, 1996
Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosisB Kaiser, J FareedSeminars in Thrombosis and Hemostasis|November 5, 1999
In vitro studies on the biochemistry and pharmacology of low molecular weight heparinsW Jeske, J FareedSeminars in Thrombosis and Hemostasis|November 5, 1999
Human pharmacokinetics of low molecular weight heparinsU Cornelli, J FareedPageof 33